Enflunib - Nanjing Sanhome Pharmaceutical
Latest Information Update: 16 Jul 2024
At a glance
- Originator Nanjing Sanhome Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
Most Recent Events
- 10 Jun 2024 Phase-I clinical trials in Acute myeloid leukaemia (unspecified route) before June 2024 (Nanjing Sanhome Pharmaceutical pipeline, June 2024)